Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NANO-X IMAGING LTD.

(NNOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Glancy Prongay & Murray LLP : a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Nano-X Imaging Ltd. (NNOX) Investors

10/14/2021 | 12:02pm EST

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities between June 17, 2021 and August 18, 2021, inclusive (the “Class Period”). Nano-X investors have until December 6, 2021 to file a lead plaintiff motion.

If you suffered a loss on your Nano-X investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/nano-x-imaging-ltd/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On August 19, 2021, Nano-X revealed that it had “received a request for additional information from the U.S. Food and Drug Administration (the ‘FDA’) concerning the Company’s last 510(k) submission of its multi-source device, Nanox.ARC.” The 510(k) submission was placed on hold pending the Company’s response.

On this news, the Company’s stock price fell $2.25 per share, or 9.5%, to close at $21.43 per share on August 19, 2021, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Nano-X's 510(k) application for the Nanox.ARC was deficient; (2) accordingly, it was unlikely that the FDA would approve the 510(k) application for the Nanox.ARC in its current form; (3) as a result, Nano-X had overstated the Nanox. ARC's regulatory and commercial prospects; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Nano-X securities during the Class Period, you may move the Court no later than December 6, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


ę Business Wire 2021
All news about NANO-X IMAGING LTD.
11/23Nanox to Host Virtual Tour of Nanox.ARC in a Clinical Setting at the Radiology Society ..
BU
11/23INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against ..
BU
11/22INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Nan..
BU
11/17Nano-X Imaging's Q3 Adjusted Loss Widens, Operating Expenses Increase
MT
11/17NANO X IMAGING : Nanox Announces Third Quarter 2021 Financial Results and Provides Busines..
PU
11/17Earnings Flash (NNOX) NANO-X IMAGING Reports Q3 Loss $-0.18, vs. Street Est of $-0.19
MT
11/17Nanox Announces Third Quarter 2021 Financial Results and Provides Business Update
BU
11/17Nano-X Imaging Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/11Nanox to Introduce New Nanox.ARC Procedures, Highlight Nanox.AI Software Solutions at 2..
BU
11/08Results of the Annual General Meeting held on November 4, 2021 - Form 6-K
PU
More news
Analyst Recommendations on NANO-X IMAGING LTD.
More recommendations
Financials (USD)
Sales 2021 0,38 M - -
Net income 2021 -63,4 M - -
Net cash 2021 114 M - -
P/E ratio 2021 -13,2x
Yield 2021 -
Capitalization 914 M 914 M -
EV / Sales 2021 2 134x
EV / Sales 2022 87,9x
Nbr of Employees 50
Free-Float 78,6%
Chart NANO-X IMAGING LTD.
Duration : Period :
Nano-X Imaging Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANO-X IMAGING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 17,69 $
Average target price 44,75 $
Spread / Average Target 153%
EPS Revisions
Managers and Directors
Ran Poliakine Chairman & Chief Executive Officer
Ran Daniel Chief Financial Officer
Ofir Koren Chief Technology Officer
Uri Shimon Vice President-Information Systems & Technology
James Dara Chief Operating Officer
Sector and Competitors